MedShare is a 501c(3) humanitarian aid organization dedicated to improving the quality of life of people, communities and our planet by channeling donated medical supplies and equipment to communities in need around the world.MedShare increases health system capacity and drives sustainability in part by providing biomedical equipment training and service to healthcare organizations and medical professionals serving populations in need.MedShare's Track Record- Has brought and continues to bring health, healing and the promise of better lives to over 100 countries.- Helped strengthen local health systems and served over 32 million people in medically under-served areas around the world.- Equipped nearly 1 million healthcare professionals in under-served communities around the world.- Supply ~1,000 under-resourced free and safety net clinics in marginalized communities.- Placed over $240 million worth of life saving medical supplies and equipment to needy communities the world over.- Provided biomedical training and support to over 7,000 healthcare professionals in 18 countries on equipment delivered to healthcare facilities around the world.- Diverted over 17.5 million pounds of quality and unused medical products from local landfills.- Built an annual volunteer corps of 16,000 humanitarians.

MedShare is a 501c(3) humanitarian aid organization dedicated to improving the quality of life of people, communities and our planet by channeling donated medical supplies and equipment to communities in need around the world.MedShare increases health system capacity and drives sustainability in part by providing biomedical equipment training and service to healthcare organizations and medical professionals serving populations in need.MedShare's Track Record- Has brought and continues to bring health, healing and the promise of better lives to over 100 countries.- Helped strengthen local health systems and served over 32 million people in medically under-served areas around the world.- Equipped nearly 1 million healthcare professionals in under-served communities around the world.- Supply ~1,000 under-resourced free and safety net clinics in marginalized communities.- Placed over $240 million worth of life saving medical supplies and equipment to needy communities the world over.- Provided biomedical training and support to over 7,000 healthcare professionals in 18 countries on equipment delivered to healthcare facilities around the world.- Diverted over 17.5 million pounds of quality and unused medical products from local landfills.- Built an annual volunteer corps of 16,000 humanitarians.

A third-generation, family-owned company founded in 1973, our services include: 1) Operational Excellence, including Business Process Management; 2) Data & Documentation, including Technical Writing; 3) IT Systems; and, 4) Project & Program Management.We have grown a lot since Joseph A. Niland founded our company in 1973, but through it all, JANA has remained privately owned. As a result, our business model is progressive, providing a unique position that allows us the flexibility to integrate new techniques and systems and the ability to change direction quickly. This has made JANA one of the most successful and cost-effective technical documentation companies in the industry.JANA has a business philosophy that has remained constant for five decades - by focusing on our customers' immediate needs and long-term growth, we can provide services that are scalable and flexible. That's "The JANA Way" - always looking beyond the quick fixes - and it has translated into many long-term corporate relationships, a fact that we are very proud of.

A third-generation, family-owned company founded in 1973, our services include: 1) Operational Excellence, including Business Process Management; 2) Data & Documentation, including Technical Writing; 3) IT Systems; and, 4) Project & Program Management.We have grown a lot since Joseph A. Niland founded our company in 1973, but through it all, JANA has remained privately owned. As a result, our business model is progressive, providing a unique position that allows us the flexibility to integrate new techniques and systems and the ability to change direction quickly. This has made JANA one of the most successful and cost-effective technical documentation companies in the industry.JANA has a business philosophy that has remained constant for five decades - by focusing on our customers' immediate needs and long-term growth, we can provide services that are scalable and flexible. That's "The JANA Way" - always looking beyond the quick fixes - and it has translated into many long-term corporate relationships, a fact that we are very proud of.

Initial efforts with Genentech focused primarily on supporting the Herceptin Development Sub-Team (DST) in completing several sBLAs and ultimately securing three separate FDA approvals in the adjuvant breast cancer setting. Thereafter joined the Avastin Gastrointestinal and Hematology DST with more than a half dozen solid tumor and hematological cancers under its remit (colon, gastric, gastrointestinal stromal tumor, carcinoid, multiple myeloma, diffuse large B-cell lymphoma, pancreatic and hepato-cellular cancer). Efforts there included helping integrate scientific and business perspective to address a variety of issues relating to C-08 & AVANT filing readiness, treatment in multiple lines, biomarkers and to some degree safety, pan-tumor issues and competition.Subquently supported the PI3-Kinase oncology program within Genentech Research and Early Development (gRED) Project Management helping the team flesh out the development strategy and orchestrate the execution one of the more ambitious early development programs in the company's pipeline (at that time), targeting a handful of cancers.In final years with the company supported the development of a next-generation anti-angiogenic agent as well as the company's broader angiogenesis diagnostic efforts.Throughout the years involved in numerous initiatives supporting Project Management as well as the broader Company, running the gamut from information and systems assessments to the training and development of other project managers. In addition, held a leading role on the Steering Committee for the Genentech’s Project Management Forum that served several hundred members across Genentech, and served for several years as the Co-Chair of the Diversity Network Association (DNA) group STAGES, which focused on helping employees navigate through change and maintain balance in their lives. As a DNA Co-Chair, also served on Genentech’s Corporate Diversity Council.

Worked with Amgen’s Research and Development (R&D) Project Management group after having joined in 2002 on the heels of the Immunex acquisition announcement. In the first year was a member of the team responsible for assessing, designing and overseeing construction of the new R&D Information Technology infrastructure across the combined entity while also working on the strategic positioning and filing of the company’s first small molecule program (Sensipar), a product with global sales today exceeding $1B. Thereafter, worked on several large molecule programs (antibodies, peptides and proteins) in various stages of development across several disease areas (nephrology, immunopathology and oncology).In final two years focused increasingly on one of the company’s largest products, Enbrel, partnering with Wyeth in seeing the psoriasis indication launched and annual dermatology sales amounting to the most successful dermatology-related launch of its time. In addition to product responsibilities, helped define numerous processes and develop templates and systems associated with a broad spectrum of product development and commercialization activities. Proposed recommendations associated with project dashboards, goals tracking, team list management, project closeouts, on-boarding and project transitions for project managers, management of study concept documents and protocols, and the sharing of best practices.

Worked at Pfizer’s world headquarters in a series of positions of increasing responsibility, culminating with holding two positions simultaneously; one as a member of Project Management Operations (PMO) helping to merge the clinical development portfolios of Pfizer and Warner Lambert while focusing on understanding the strategic fit as well as resource and capacity implications of the merged entity, and the other as a headquarters’ representative supporting the sales organization’s efforts for all products in a tri-state area (NY, MA, VT) where I participated in monthly strategy and execution discussions with District and Regional Sales Managers responsible for more than six field forces covering Pfizer’s entire portfolio. Appointed to the first Global Development Team (GDT) with the migraine agent Relpax, and as global program manager shepherded the product through filing and approval.Prior to the GDT experience. worked in marketing and marketing operations capacities within Pfizer’s International Pharmaceuticals Group (IPG). Contributions in those roles ranged from spearheading the onychomycosis launch plan for Diflucan to developing a best practice-sharing program for Zithromax to architecting numerous informational-based initiatives that served as the basis for sharing information and best practices across Pfizer’s global business. During the initial years, worked in the Business Intelligence & Planning Group within IPG: Performed due diligence associated with acquisition candidates; Analyzed the portfolios of Pfizer and its key competitors; Examined healthcare reform and the subacute care industry in the US; Performed an in-depth assessment of the Japanese market, including its sales environment, and projected possible market developments; and, Analyzed the global generic marketplace and the Chinese marketplace to support local marketing efforts and the selection of products for production in Pfizer’s plant in Dalian, China.